ANTIBODY DETECTION OF MISMATCH REPAIR PROTEINS

Abstract: Antibodies directed to human protein mismatch repair proteins can be used diagnostically to discriminate between proliferating and non-proliferating cells. In addition, they can be used to determine whether cells have a mismatch repair defect caused by a mutation in e.g., hMSH2, hMLH1, or hPMS2. They can also be used to monitor the efficacy of anti-neoplastic therapies.

Description: ANTIBODY DETECTION OF MISMATCH REPAIR PROTEINS BACKGROUND OF THE INVENTION HNPCC (Lynch syndrome) is one of the most common cancer predisposition syndromes, affecting as many as 1 in 200 individuals in the western world (Lynch et al., 1993). Affected individuals develop tumors of the colon, endometrium, ovary and other organs, often before 50 years of age. Although the familial nature of this syndrome was discovered nearly a century ago (Warthin et al., 1913), the role of heredity in its causation remained difficult to define (Lynch et al., 1966). Recently, however, linkage analysis in two large kindreds demonstrated association with polymorphic markers on chromosome 2 (Peltomaki et al., 1993a). Studies in other families suggested that neoplasia in a major fraction of HNPCC kindreds is linked to this same chromosome 2p locus (Aaltonen et al., 1993). HNPCC is defined clinically by the occurrence of early-onset colon and other specific cancers in first degree relatives spanning at least two generations (Lynch et al., 1993). The predisposition is inherited in an autosomal dominant fashion. It was initially expected that the gene(s) responsible for HNPCC would be a tumor suppressor gene, as other previously characterized cancer predisposition syndromes with this mode of inheritance are caused by suppressor gene mutations (reviewed in Knudson, 1993). But the analysis of tumors from HNPCC patients suggested a different mechanism. Most loci encoding tumor suppressor genes undergo somatic losses during tumorigenesis (Stanbridge, 1990). In contrast, both alleles of chromosome 2p loci were found to be retained in HNPCC tumors (Aaltonen et al., 1993). During this search for chromosome 2 losses, however, it was noted that HNPCC tumors exhibited somatic alterations of numerous microsatellite sequences. Widespread, subtle alterations of the cancer cell genome were first detected in a subset of sporadic colorectal tumors using the arbitrarily-primed polymerase chain reaction (Peinado et al., 1992). These alterations were subsequently found to represent deletions of up to 4 nucleotides in genomic poly A tracts (Ionov et al., 1993). Other studies showed that a similar, distinctive subgroup of sporadic tumors had insertions or deletions in a variety of simple repeated sequences, •particularly microsatellite sequences consisting of dinucleotide or trinucleotide repeats (Ionov et al., 1993; Thibodeau et al., 1993; Aaltonen et al., 1993). Interestingly, these sporadic tumors had certain features in common with those developing in HNPCC kindreds, such as a tendency to be located on the right side of the colon and to be near-diploid. These and other data suggested that HNPCC and a subset of sporadic tumors were associated with a heritable defect causing replication errors (RER) of microsatellites (Ionov et al., 1993; Aaltonen et al., 1993). _ « _ The mechanism underlying the postulated defect could not be determined from the study of tumor DNA, but studies in simpler organisms provided an intriguing possibility (Levinson and Gutman, 1987; Strand et al., 1993). This work showed that bacteria and yeast containing defective mismatch repair genes manifest instability of dinucleotide repeats. The disruption of genes primarily involved in DNA replication or recombination had no apparent effect on the fidelity of microsatellite replication (reviewed in Kunkel, 1993). These pivotal studies suggested that defective mismatch repair might be responsible for the microsatellite alterations in the tumors from HNPCC patients (Strand et al. , 1993). This hypothesis was proven when HMSH2, one of the genes responsible for HNPCC, was identified. Leach et al., (1993); Fishel, et al., (1993). There is a need in the art for methods of diagnosing and prognosing mismatch repair defects involved in inherited and somatic cancers. Such tumors have a more favorable prognosis than others. There is also a need in the art for improved methods for assessing the proliferative index of cells which index can be used as a prognostic factor in cancers. SUMMARY OF THE INVENTION It is an object of the invention to provide a method of discriminating proliferating from non-proliferating cells in a tissue. It is another object of the invention to provide a method for determining a mismatch repair defect, such as in hMSH2, hMLHl, or hPMS2 genes in tumor cells. It is yet another object of the invention to provide a method of monitoring the effectiveness of anti-cancer therapy in neoplastic tissue. It is still another object of the invention to provide methods for discriminating between proliferating and non-proliferating cells. It is an object of the invention to provide a method of identifying tumor- bearing individuals. These and other objects of the invention are provided by one or more of the embodiments shown below. In one embodiment of the invention a method is provided of discriminating proliferating from non-proliferating cells in a tissue. The method comprises the steps of: contacting a tissue comprising cells with antibodies specifically immunoreactive with a mismatch repair protein, to form antibody-antigen complexes; and determining the presence of said antibody-antigen complexes in said cells, said presence indicating proliferating cells. In another embodiment of the invention a method is provided for determining a mismatch repair defect in a mismatch repair gene, such as hMSH2, hMLHl, or hPMS2, in tumor cells, comprising the steps of: contacting a tissue comprising cells with antibodies specifically immunoreactive with a mismatch repair protein to form antibody-antigen complexes; and determining nuclear or non-nuclear localization of said antibody-antigen complexes, lack of nuclear staining indicating a defect in a mismatch repair gene. In yet another embodiment of the invention, a method is provided for monitoring the effectiveness of anti-cancer therapy in neoplastic tissue. The method comprises the steps of: contacting a sample of a neoplastic tissue which has been subjected to an anti-cancer therapy with antibodies specifically immunoreactive with a mismatch repair protein to form antibody-antigen complexes; determining the amount of said antibody-antigen complexes in said sample; and comparing the amount of antibody-antigen complexes in said sample with an amount determined at an earlier time, a reduction in the amount of antibody-antigen complexes indicating effective therapy. According to yet another embodiment of the invention, a method is provided for discriminating proliferating from non-proliferating cells. The method comprises the steps of: preparing a lysate of cells to be tested; contacting said lysate with antibodies specifically immunoreactive with a mismatch repair protein to form antibody-antigen complexes; and deterπώύng the amount of antibody-antigen complexes formed in said lysate, a lysate of test cells which provides more antibody-antigen complexes than control lysates of non-tumor cells indicating that the test cells are proliferating. In still another embodiment of the invention, a method is provided for discriminating proliferating from non-proliferating cells. The method comprises the steps of: isolating nuclei of cells to be tested; preparing a lysate of said nuclei of said cells to be tested; contacting said lysate with antibodies specifically immunoreactive with a mismatch repair protein to form antibody-antigen complexes; and deteπnining the amount of antibody-antigen complexes formed in said lysate, a lysate of nuclei which provides more antibody-antigen complexes than control lysates of non-tumor cell nuclei indiating that the test cells are proliferating. According to yet another embodiment of the invention, a method is provided for identifying tumor-bearing individuals. The method comprises the step of: detecting auto-antibodies to a mismatch repair protein in a human, wherein presence of said auto-antibodies indicates the presence of a tumor in the human. The invention thus provides the art with immunological assays which can provide diagnostic and prognostic information to improve the assessment of cancers and the evaluation of treatment options. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a gel of an immunoprecipitation of MSH2 from colorectal tumor cells using anti-MSH2 monoclonal antibody (mAb) FE11 and EH12. Figure 1 shows that both antibodies immunoprecipitate a 100 kDa protein from HCT116 cells, which express wild type MSH2. The protein is not seen in LoVo cells. In addition, a 160 kDa protein is also detected as part of a co-precipitating complex, but only in the HCT116 cells. NMS is normal mouse serum used as a negative control. Figure 2 shows a comparison of three cell lines by immunoblot. SW480 cells express only wild type MSH2. LoVo cells do not express any MSH2 due to homozygous loss of both alleles. The cell line KK expresses both a full length wild type MSH2 and a smaller form, due to an in-frame deletion of SO amino acids. Identification of the shortened form of MSH2 is indicative of the presence of mutation in the MSH2 gene. Figure 3 shows immunohistochemical staining of MSH2 in normal colon with either FEll or EH12. Figure 3A shows detection of MSH2 in paraffin-embedded tissue with EH12 while Figure 3B shows detection of MSH2 in frozen tissue with FEll. In both cases, staining is nuclear and is predominantly localized to the lower portion of crypts which is associated with the proliferating compartment of the colonic epithelium. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The MSH2 gene is one of at least four genes encoding proteins involved in the repair of mismatched nucleotides following DNA replication or repair. Mutations in the MSH2 gene contribute to the development of sporadic colorectal carcinoma, while germline MSH2 mutations are responsible for approximately 50% of inherited, non-polyposis colorectal carcinoma (HNPCC). Since MSH2 is ubiquitously expressed, development of other cancers besides colorectal carcinoma are also susceptible to alterations in MSH2. Studies of HNPCC families have shown that MSH2 mutations can be internal, in-frame deletions or chain-terminating mutations. To characterize both wild-type and mutant MSH2 proteins, we have generated a series of monoclonal antibodies specifically immunoreactive with the human MSH2 protein (hMSH2). The antibodies do not immunoreact with other human proteins. Western blotting with the monoclonal antibodies demonstrates that normal cells and some colorectal tumor lines (i.e., SW480) express wild-type, full-length, 100 kDa MSH2 protein, whereas a cell line derived from an HNPCC patient carrying an in-frame deletion in one allele of MSH2 expresses both a full-length and, at lpw level, a shorter form. Other colorectal cancer cell lines are devoid of MSH2 protein due to either homozygous loss of MSH2 (LoVo cells, for example), instability of aberrant MSH2 protein expressed from mutant alleles, or mutations in other HNPCC genes that result in premature degradation of wild type MSH2 protein. Thus such antibodies can be used to detect loss of wild-type MSH2 proteins. A number of surprising properties of the antibodies have been discovered. First, the MSH2 protein is expressed strongly in proliferating but not in non- proliferating cells. Second, the cellular localization of MSH2 protein is dependent upon the mismatch repair status of the cell. Mutations in any of the mismatch repair genes, including but not limited to the hMSH2, hMLHl, and hPMS2 genes causes the MSH2 protein to be aberrantly localized extra-nuclearly. If a cell is wild-type for the mismatch repair genes, the protein is mainly nuclear. Similarly other mismatch repair proteins are aberrantly localized when any one is mutated. The ability to score a proliferative index of cells on the basis of antibody binding, rather than using radiolabeled deoxyribonucleotides, provides major practical, cost, and safety advantages. It also allows for monitoring of anti-cancer therapies on the basis of the proliferative index of the cells being treated without use of radionuclides. Successful treatment will lower the proliferative index of cancer cells. Detection of a failure to lower the proliferative index or to lower it sufficiently will allow other doses or regimens to be tried, or other anti-neoplastic agents to be used. Proliferation can be assessed using standard immunological methods, including, but not limited to immunohistochemistry, immunofluorescence, and fluorescence activating cell sorting. In addition, lysates of cells can be prepared and tested directly to determine the amount of a mismatch repair protein expressed. Similarly, nuclei of cells can be isolated and lysed, and the lysate can be assayed for mismatch repair protein expression, typically through the use of antibodies. With lysates, enzyme linked immunosorbent assays can be used conveniently. The observation that MSH2 is more heavily expressed in highly proliferative cancer cells than in normal cells may account for the expression of auto-antibodies to a mismatch repair protein in some cancer patients during the course of their disease. The detection of auto-antibodies to a mismatch repair protein in human subjects can be used diagnostically as an indication of the presence of a tumor in the body. Proliferating cells can be discriminated from non-proliferating cells in a tissue using the antibodies disclosed herein. Antibodies are contacted with a tissue. Immune complexes of antibody and antigen are detected using, for example, immunohistochemistry or immunofluorescence or fluorescence activated cell sorting. The presence of immune complexes comprising the antibodies in the cells being tested indicates a proliferative state for those cells. Immunohistochemistry performed using antibodies to specifically detect MSH2 has shown that proliferating cells that express wild-type MSH2 protein are readily detected whereas non-proliferating cells are not detected. The ability to correlate cell proliferation with mismatch repair protein expression provides a means of assessing the proliferative state of a tissue simply by examining cells for mismatch repair protein expression by immunological methods. Any cell expressing only wild type forms of MSH2, MLHl, and PMS2 genes and undergoing proliferation will be detected by immunodetection methods using anti-mismatch repair protein monoclonal and/or polyclonal antibodies. Non-proliferating cells will not be detected due to lack of nuclear-localized mismatch repair protein. The overall degree of proliferation of cells in a tissue is positively correlated with the level of mismatch repair protein detected. Highly proliferative cells show high levels of nuclear localized a mismatch repair protein by immunohistochemistry or by flow cytometry or by immunofluorescence, whereas cells growing more slowly have reduced levels of mismatch repair protein. Normal cells can be used as controls, either from matched tissues of the individual being tested in the case of immunohistochemistry, or from other normal individuals. Often it will be desirable to test a population of normal individuals to determine a range of normal values of expression of a mismatch repair protein. Typically values which are more than two standard deviations outside of the mean of the normals are considered aberrant. The setting of the range of normals versus aberrants is a matter of routine experimentation familiar to those of skill in the art. Mismatch repair defects due to mutations in genes such as hMSH2, hMLHl, or hPMS2, in tumor cells can be determined readily using antibodies according to the present invention. Cancer cells that do not have mutations in MSH2, MLH1, or PMS2 allow detection of MSH2 whereas cancer cells with a mutation in any of the mismatch repair genes do not exhibit a wild-type pattern of mismatch repair protein expression as determined by immunohistochemical methods. Wild-type pattern of expression is nuclear, whereas mutations in the mismatch repair genes lead to loss of nuclear expression and staining. Furthermore, since alterations in the MSH2, MLHl, or PMS2 genes lead to altered mismatch repair protein expression, one can determine whether a cell line has defective DNA repair functions as demonstrated by aberrant mismatch repair protein detection in immunohistochemistry. Quantitation of mismatch repair protein can also be performed by enzyme linked immunosorbent assay (ELISA) in which mismatch repair protein is captured with one set of antibodies and then detected and quantitated with a second set of antibodies. The second set of antibodies can be directed against the mismatch repair protein or against proteins that form stable complexes in vivo with the mismatch repair protein. Alternatively, detection of captured mismatch repair protein can be performed by measuring the ability of a DNA segment containing appropriate mismatched nucleotides to be stably bound by the mismatch repair protein. Immunoprecipitation of MSH2 protein with anti-MSH2 protein antibodies has been found to co-precipitate one or more additional proteins from lysates of normal cells but not cancer cells that are null for MSH2. Such proteins may be accessory proteins involved in mismatch repair. One such protein has an apparent molecular weight of 160 kDa. The methods of the present invention rely on polyclonal or monoclonal antibodies that are highly specific for human mismatch repair proteins which are used according to defined protocols. We achieved specificity by first, immunizing mice with a recombinant form of MSH2 expressed in E. coli and purified to homogeneity by electroelution form SDS/PAGE. After a series of immunizations, mouse sera was checked for anti-MSH2 reactivity by: (1) ELISA using microtitre plates coated with GST-MSH2 antigen for positive reactivity; (2) western blotting using HCT116 or SW480 cells to detect the plOO MSH2 protein; and (3) western blotting using LoVo cells in which no plOO MSH2 is expected. After fusion of hyperimmunized mouse spleen cells to SP2/O cells, all resulting hybridomas were screened by ELISA using GST-MSH2 fusion proteins. MSH2-reactive hybridomas were subcloned twice by limiting dilution and rescreened by ELISA. Resulting stable clones were then tested by western blotting and specificity of a given monoclonal antibody was determined by comparing the signals generated from known positive and negative controls. This could be done using induced versus uninduced cell lines in which an exogenously added agent is used to turn on expression of the desired gene product. An antibody specific for the antigen of interest would detect the antigen only in lysates from the induced cells and no other proteins and not detect any proteins in the uninduced lysates. Alternatively, in cases where the genetic status is known, cells carrying a wild-type allele are compared to cells that are null for the gene in question. With MSH2, HCT116 cells are known to have a wild-type MSH2 allele and express MSH2 mRNA whereas LoVo cells have a homozygous deletion of MSH2. By either western blotting or immunoprecipitation, the 100 kDa MSH2 protein is detected only in HCT116 cells and no 100 kDa protein is seen in LoVo cells. In some cases, multiple non-specific bands will be seen depending on various conditions such as impure primary antibody, non-specific secondary antibody, extended exposure times when using chemiluminescence, poor sample preparation or handling. See the following references regarding immunological methods: WO 94/21814, Smith, K. et al., The APC Gene Product in Normal and Tumor Cells. Proc. Natl. Acad. Sci., USA 90: 2846-2850, 1993, or the manual by Harlow and Lane. Examples To characterize both wild type and mutant MSH2 proteins, we have generated a series of monoclonal antibodies to the human MSH2 protein. 1) Antigen and Immunizations The antigens used to immunize mice were bacterial expressed, purified glutathione-S-transferase-MSH2 (GST-MSH2) fusion proteins. The GST-MSH2-NH fusion protein contains the 300 extreme amino-terminal MSH2 amino acids. The GST-MSH2-COOH fusion protein contains the 300 extreme carboxy-terminal MSH2 amino acids. Each was purified by separating the inclusion bodies containing the fusion proteins, by SDS-polyacrylamide gel electrophoresis. The band corresponding to the correct molecular weight was then cut out of the gel and the protein electroeluted out of the gel slice. One group of mice was immunized with the purified GST-MSH2-NH fusion protein and a second group of mice was immunized with the purified GST-MSH2-COOH fusion protein. Each of the purified fusion proteins were mixed with RIBI adjuvant prior to immunizations. 2) Fusions and Screening One mouse which had been injected with carboxy-terminal fusion protein was sacrificed and its spleen cells fused to SP2/O cells. The resulting hybridomas were screened by ELISA on purified GST-MSH2-COOH-coated microtiter plates. Positive wells were further screened by western blot for specificity to a 100 kD protein present in HCT-116 lysates but not in LoVo lysates. Western blot-positive hybridomas were single cell subcloned twice and then put into mice for ascites production. The hybridomas FEll and EH12 resulted from this fusion. A second mouse, one that had been immunized with the amino terminal GST-MSH2 fusion protein, was sacrificed and its spleen cells fused to SP2/Os. Hybridomas were screened and subcloned as above, except that the initial ELISA was performed using GST-MSH2-NH-coated microtitre plates to identify hybridomas expressing antibodies reactive to the amino-terminal portion of MSH2 protein. Hybridoma GB12 resulted from this fusion. 3) Characterization of Antibodies by Western Blot and Immunoprecipitation and Immunohistochemistry FEll, EH12 and GB12 all recognize the 100 kD MSH2 protein in HCT-116 lysates by western blot and immunoprecipitation. No 100 kD protein is detected by western blot or immunoprecipitated in LoVo lysates which are null for MSH2. In addition, EH12 produces nuclear staining in formalin-fixed, paraffin-embedded, normal colon sections, localized in the proliferating cells at the base of the crypts of Lieberkuhn. FEll stains frozen tissue sections. The MSH2 gene encodes a protein of 934 amino acids. Normal cells and some colorectal tumor lines (i.e., SW480) express wild-type, full-length 100 kDa MSH2 protein whereas a cell line derived from an HNPCC patient (KK) carrying an in-frame deletion in one allele of MSH2 expresses both a full length and, at low level, a shorter species corresponding to the size expected for the 880 amino acid form. The LoVo colorectal line is devoid of MSH2 protein due to homozygous loss of MSH2. Many of the mutations in the MSH2 gene are truncating ones; that is, they introduce small deletions or base changes that result in expression of a shortened form of the 100 kDa wild-type MSH2 protein. All anti-MSH2 mAbs were also evaluated for the ability to detect MSH2 protein by immunohistochemical methods. MSH2 protein is ordinarily localized to the nucleus. FEll and EH12 detect nuclear-lαalized MSH2 in frozen sections or in tissue culture cells immobilized and fixed in microtitre wells and EH12 can be used to detect MSH2 protein in formalin-fixed, paraffin-embedded tissue. Since the DNA repair machinery involves at least four different gene products, we examined cell lysates for stable complexes of MSH2 and other proteins by immunoprecipitating, with either mAb FEll or EH12, MSH2 from cells lysed under conditions that would preserve protein-protein interactions. Biochemical analysis of DNA mismatch repair in yeast had suggested that the yeast homolog of MSH2 is not ordinarily associated with other known DNA repair factors in the absence of mismatched DNA duplexes. Figure 1 shows that in HCT 116 cells, which express wild-type MSH2, both antibodies immunoprecipitated a 160 kDa protein that is part of a co-precipitating complex with the 100 kDa MSH2 protein. This is not an alternative form of MSH2 or an MSH2 dimer since an immunoprecipitation with either FEll or EH12 followed by immunoblotting with EH12 detects only the plOO MSH2 protein. References Aaltonen, L.A., Peltomaki, P., Leach, F.S., Sistonen, P., Pylkkanen, L., Mecklin, J-P., Jarvinen, H., Powell, S.M., Jen, J., Hamilton, S.R., Petersen, G.M., Kinzler, K.W., Vogelstein, B., and de la Chapelle, A. (1993). Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-816. Fishel et al. (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1927-1038. Ionov, Y.M., Peinado, A., Malkhosyan, S., Shibata, D., and Perucho M. (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363, 558-561. Knudson, A.G. (1993). All in the (cancer) family. Nature Genetics 5, 103-104. Kunkel, T.A. (1993). Slippery DNA and diseases. Nature 365, 207-208. Leach et al. (1993) Mutations of a MutS Homolog in Hereditary Non-Polyposis Colorectal Cancer. Cell, 75, 1215-1225. Lynch, H.T., Omaha, M.W., Shaw, M.D. (1966). Hereditary factors in cancer. Arch Intern Med 117, 206-212. Lynch, H.T., Smyrk, T.C., Watson, P., Lanspa, S.J., Lynch, J.F., Lynch, P.M., Cavalieri, R.J., and Boland, CR. (1993). Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology 104, 1535-1549. Peinado, M.A., Malkhosyan, S., Velazquez, A., and Perucho, M. (1992). Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc. Natl. Acad. Sci. USA 89, 10065-10069. Stanbridge, E.J. (1990). Human tumor suppressor genes. Ann. Rev. Genes 24, 615- 657. Strand, M., Prolla, T.A., Liskay, R.M., and Petes, T.D. (1993). Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 365, 274-276. Thibodeau, S.N., Bren, G., and Schaid, D. (1993). Microsatellite instability in cancer of the proximal colon. Science 260, 816-819. Warthin, A.S. (1913). Heredity with reference to carcinoma: As shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch. Int. Med 12, 546-555. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Kinzler, Kenneth W. Vogelstein, Bert Burrell, Marilee Hill, David E. (ii) TITLE OF INVENTION: Antibody Detection of Mismatch Repair Protein (iii) NUMBER OF SEQUENCES: 3 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Banner & Allegretti, Ltd. (B) STREET: 1001 G Street, N.W. (C) CITY: Washington (D) STATE: D.C. (E) COUNTRY: U.S.A. (F) ZIP: 20001-4597 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 08/480,351 (B) FILING DATE: 07- UN-1995 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Kagan, Sarah A. (B) REGISTRATION NUMBER: 32,141 (C) REFERENCE/DOCKET NUMBER: 1107.49332 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 202-508-9100 (B) TELEFAX: 202-508-9299 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 934 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (iv) ANTI-SENSE: NO (Vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: Met Ala Val Gin Pro Lys Glu Thr Leu Gin Leu Glu Ser Ala Ala Glu 1 5 10 15 - 18 - Val Gly Phe Val Arg Phe Phe Gin Gly Met Pro Glu Lys Pro Thr Thr 20 25 30 Thr Val Arg Leu Phe Asp Arg Gly Asp Phe Tyr Thr Ala His Gly Glu 35 40 45 Asp Ala Leu Leu Ala Ala Arg Glu Val Phe Lys Thr Gin Gly Val lie 50 55 60 Lys Tyr Met Gly Pro Ala Gly Ala Lys Asn Leu Gin Ser Val Val Leu 65 70 75 80 Ser Lys Met Asn Phe Glu Ser Phe Val Lys Asp Leu Leu Leu Val Arg 85 90 95 Gin Tyr Arg Val Glu Val Tyr Lys Asn Arg Ala Gly Asn Lys Ala Ser 100 105 110 Lys Glu Asn Asp Trp Tyr Leu Ala Tyr Lys Ala Ser Pro Gly Asn Leu 115 120 125 Ser Gin Phe Glu Asp lie Leu Phe Gly Asn Asn Asp Met Ser Ala Ser 130 135 140 He Gly Val Val Gly Val Lys Met Ser Ala Val Asp Gly Gin Arg Gin 145 150 155 160 Val Gly Val Gly Tyr Val Asp Ser He Gin Arg Lys Leu Gly Leu Cys 165 170 175 Glu Phe Pro Asp Asn Asp Gin Phe Ser Asn Leu Glu Ala Leu Leu He 180 185 190 Gin He Gly Pro Lys Glu Cys Val Leu Pro Gly Gly Glu Thr Ala Gly 195 200 205 Asp Met Gly Lys Leu Arg Gin He He Gin Arg Gly Gly He Leu He 210 215 220 Thr Glu Arg Lys Lys Ala Asp Phe Ser Thr Lys Asp He Tyr Gin Asp 225 230 235 240 Leu Asn Arg Leu Leu Lys Gly Lys Lys Gly Glu Gin Met Asn Ser Ala 245 250 255 Val Leu Pro Glu Met Glu Asn Gin Val Ala Val Ser Ser Leu Ser Ala 260 265 270 Val He Lys Phe Leu Glu Leu Leu Ser Asp Asp Ser Asn Phe Gly Gin 275 280 285 Phe Glu Leu Thr Thr Phe Asp Phe Ser Gin Tyr Met Lys Leu Asp He 290 295 300 Ala Ala Val Arg Ala Leu Asn Leu Phe Gin Gly Ser Val Glu Asp Thr 305 310 315 320 Thr Gly Ser Gin Ser Leu Ala Ala Leu Leu Asn Lys Cys Lys Thr Pro 325 330 335 Gin Gly Gin Arg Leu Val Asn Gin Trp He Lys Gin Pro Leu Met Asp 340 345 350 Lys Asn Arg He Glu Glu Arg Leu Asn Leu Val Glu Ala Phe Val Glu 355 360 365 Asp Ala Glu Leu Arg Gin Thr Leu Gin Glu Asp Leu Leu Arg Arg Phe 370 375 380 Pro Asp Leu Asn Arg Leu Ala Lys Lys Phe Gin Arg Gin Ala Ala Asn 385 390 395 400 Leu Gin Asp Cys Tyr Arg Leu Tyr Gin Gly He Asn.Gin Leu Pro Asn 405 410 415 Val He Gin Ala Leu Glu Lys His Glu Gly Lys His Gin Lys Leu Leu 420 425 430 Leu Ala Val Phe Val Thr Pro Leu Thr Asp Leu Arg Ser Asp Phe Ser 435 440 445 Lys Phe Gin Glu Met He Glu Thr Thr Leu Asp Met Asp Gin Val Glu 450 455 460 Asn His Glu Phe Leu Val Lys Pro Ser Phe Asp Pro Asn Leu Ser Glu 465 470 475 480 Leu Arg Glu He Met Asn Asp Leu Glu Lys Lys Met Gin Ser Thr Leu 485 490 495 He Ser Ala Ala Arg Asp Leu Gly Leu Asp Pro Gly Lys Gin He Lys 500 505 510 Leu Asp Ser Ser Ala Gin Phe Gly Tyr Tyr Phe Arg Val Thr Cys Lys 515 520 525 Glu Glu Lys Val Leu Arg Asn Asn Lys Asn Phe Ser Thr Val Asp He 530 535 540 Gin Lys Asn Gly Val Lys Phe Thr Asn Ser Lys Leu Thr Ser Leu Asn 545 550 555 560 Glu Glu Tyr Thr Lys Asn Lys Thr Glu Tyr Glu Glu Ala Gin Asp Ala 565 570 575 He Val Lys Glu He Val Asn He Ser Ser Gly Tyr Val Glu Pro Met 580 585 590 Gin Thr Leu Asn Asp Val Leu Ala Gin Leu Asp Ala Val Val Ser Phe 595 600 605 Ala His Val Ser Asn Gly Ala Pro Val Pro Tyr Val Arg Pro Ala He 610 615 620 Leu Glu Lys Gly Gin Gly Arg He He Leu Lys Ala Ser Arg His Ala 625 630 635 640 Cys Val Glu Val Gin Asp Glu He Ala Phe He Pro Asn Asp Val Tyr 645 650 655 Phe Glu Lys Asp Lys Gin Met Phe His He He Thr Gly Pro Asn Met 660 665 670 Gly Gly Lys Ser Thr Tyr He Arg Gin Thr Gly Val He Val Leu Met 675 680 685 Ala Gin He Gly Cys Phe Val Pro Cys Glu Ser Ala Glu Val Ser He 690 695 700 Val Asp Cys He Leu Ala Arg Val Gly Ala Gly Asp Ser Gin Leu Lys 705 710 715 720 Gly Val Ser Thr Phe Met Ala Glu Met Leu Glu Thr Ala Ser He Leu 725 730 735 Arg Ser Ala Thr Lys Asp Ser Leu He He He Asp Glu Leu Gly Arg 740 745 750 Gly Thr Ser Thr Tyr Asp Gly Phe Gly Leu Ala Trp Ala He Ser Glu 755 760 765 Tyr He Ala Thr Lys He Gly Ala Phe Cys Met Phe Ala Thr His Phe 770 775 780 His Glu Leu Thr Ala Leu Ala Asn Gin He Pro Thr Val Asn Asn Leu 785 790 795 800 His Val Thr Ala Leu Thr Thr Glu Glu Thr Leu Thr Met Leu Tyr Gin 805 810 815 Val Lys Lys Gly Val Cys Asp Gin Ser Phe Gly He His Val Ala Glu 820 825 830 Leu Ala Asn Phe Pro Lys His Val He Glu Cys Ala Lys Gin Lys Ala 835 840 845 Leu Glu Leu Glu Glu Phe Gin Tyr He Gly Glu Ser Gin Gly Tyr Asp 850 855 860 He Met Glu Pro Ala Ala Lys Lys Cys Tyr Leu Glu Arg Glu Gin Gly 865 870 875 880 Glu Lys He He Gin Glu Phe Leu Ser Lys Val Lys Gin Met Pro Phe 885 890 895 Thr Glu Met Ser Glu Glu Asn He Thr He Lys Leu Lys Gin Leu Lys 900 905 910 Ala Glu Val He Ala Lys Asn Asn Ser Phe Val Asn Glu He He Ser 915 920 925 Arg He Lys Val Thr Thr 930 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 856 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Glu Arg Ala Glu Ser Ser Ser Thr Glu Pro Ala Lys Ala He Lys 1 5 10 15 Pro He Asp Arg Lys Ser Val His Gin He Cys Ser Gly Gin Val Val 20 25 30 Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp 35 40 45 Ala Gly Ala Thr Asn He Asp Leu Lys Leu Lys Asp Tyr Gly Val Asp 50 55 60 Leu He Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe 65 70 75 80 Glu Gly Leu Thr Leu Lys His His Thr Ser Lys He Gin Glu Phe Ala 85 90 95 Asp Leu Thr Gin Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser 100 105 110 Ser Leu Cys Ala Leu Ser Asp Val Thr He Ser Thr Cys His Ala Ser 115 120 125 Ala Lys Val Gly Thr Arg Leu Met Phe Asp His Asn Gly Lys He He 130 135 140 Gin Lys Thr Pro Tyr Pro Arg Pro Arg Gly Thr Thr Val Ser Val Gin 145 150 155 160 Gin Leu Phe Ser Thr Leu Pro Val Arg His Lys Glu Phe Gin Arg Asn 165 170 175 He Lys Lys Glu Tyr Ala Lys Met Val Gin Val Leu His Ala Tyr Cys 180 185 190 He He Ser Ala Gly He Arg Val Ser Cys Thr Asn Gin Leu Gly Gin 195 200 205 Gly Lys Arg Gin Pro Val Val Cys Thr Gly Gly Ser Pro Ser He Lys 210 215 220 Glu Asn He Gly Ser Val Phe Gly Gin Lys Gin Leu Gin Ser Leu He 225 230 235 240 Pro Phe Val Gin Leu Pro Pro Ser Asp Ser Val Cys Glu Glu Tyr Gly 245 250 255 Leu Ser Cys Ser Asp Ala Leu His Asn Leu Phe Tyr He Ser Gly Phe 260 265 270 He Ser Gin Cys Thr His Gly Val Gly Arg Ser Ser Thr Asp Arg Gin 275 280 285 Phe Phe Phe He Asn Arg Arg Pro Cys Asp Pro Ala Lys Val Cys Arg 290 295 300 Leu Val Asn Glu Val Tyr His Met Tyr Asn Arg His Gin Tyr Pro Phe 305 310 315 320 Val Val Leu Asn He Ser Val Asp Ser Glu Cys Val Asp He Asn Val 325 330 335 Thr Pro Asp Lys Arg Gin He Leu Leu Gin Glu Glu Lys Leu Leu Leu 340 345 350 Ala Val Leu Lys Thr Ser Leu He Gly Met Phe Asp Ser Asp Val Asn 355 360 365 - 22 - Lys Leu Asn Val Ser Gin Gin Pro Leu Leu Asp Val Glu Gly Asn Leu 370 375 380 He Lys Met His Ala Ala Asp Leu Glu Lys Pro Met Val Glu Lys Gin 385 390 395 400 Asp Gin Ser Pro Ser Leu Arg Thr Gly Glu Glu Lys Lys Asp Val Ser 405 410 415 He Ser Arg Leu Arg Glu Ala Phe Ser Leu Arg His Thr Thr Glu Asn 420 425 430 Lys Pro His Ser Pro Lys Thr Pro Glu Pro Arg Arg Ser Pro Leu Gly 435 440 445 Gin Lys Arg Gly Met Leu Ser Ser Ser Thr Ser Gly Ala He Ser Asp 450 455 460 Lys Gly Val Leu Arg Pro Gin Lys Glu Ala Val Ser Ser Ser His Gly 465 470 475 480 Pro Ser Asp Pro Thr Asp Arg Ala Glu Val Glu Lys Asp Ser Gly His 485 490 495 Gly Ser Thr Ser Val Asp Ser Glu Gly Phe Ser He Pro Asp Thr Gly 500 505 510 Ser His Cys Ser Ser Glu Tyr Ala Ala Ser Ser Pro Gly Asp Arg Gly 515 520 525 Ser Gin Glu His Val Asp Ser Gin Glu Lys Ala Pro Glu Thr Asp Asp 530 535 540 Ser Phe Ser Asp Val Asp Cys His Ser Asn Gin Glu Asp Thr Gly Cys 545 550 555 560 Lys Phe Arg Val Leu Pro Gin Pro Thr Asn Leu Ala Thr Pro Asn Thr 565 570 575 Lys Arg Phe Lys Lys Glu Glu He Leu Ser Ser Ser Asp He Cys Gin 580 585 590 Lys Leu Val Asn Thr Gin Asp Met Ser Ala Ser Gin Val Asp Val Ala 595 600 605 Val Lys He Asn Lys Lys Val Val Pro Leu Asp Phe Ser Met Ser Ser 610 615 620 Leu Ala Lys Arg He Lys Gin Leu His His Glu Ala Gin Gin Ser Glu 625 630 635 640 Gly Glu Gin Asn Tyr Arg Lys Phe Arg Ala Lys He Cys Pro Gly Glu 645 650 655 Asn Gin Ala Ala Glu Asp Glu Leu Arg Lys Glu He Ser Lys Thr Met 660 665 670 Phe Ala Glu Met Glu He He Gly Gin Phe Asn Leu Gly Phe He He 675 680 685 Thr Lys Leu Asn Glu Asp He Phe He Val Asp Gin His Ala Thr Asp 690 695 700 Glu Lys Tyr Asn Phe Glu Met Leu Gin Gin His Thr Val Leu Gin Gly 705 710 715 720 Gin Arg Leu He Ala Pro Gin Thr Leu Asn Leu Thr Ala Val Asn Glu 725 730 735 Ala Val Leu He Glu Asn Leu Glu He Phe Arg Lys Asn Gly Phe Asp 740 745 750 Phe Val He Asp Glu Asn Ala Pro Val Thr Glu Arg Ala Lys Leu He 755 760 765 Ser Leu Pro Thr Ser Lys Asn Trp Thr Phe Gly Pro Gin Asp Val Asp 770 775 780 Glu Leu He Phe Met Leu Ser Asp Ser Pro Gly Val Met Cys Arg Pro 785 790 795 800 Ser Arg Val Lys Gin Met Phe Ala Ser Arg Ala Cys Arg Lys Ser Val 805 810 815 Met He Gly Thr Ala Leu Asn Thr Ser Glu Met Lys Lys Leu He Thr 820 825 830 His Met Gly Glu Met Asp His Pro Trp Asn Cys Pro His Gly Arg Pro 835 840 845 Thr Met Arg His He Ala Asn Leu 850 855 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 752 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: YES (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Ser Phe Val Ala Gly Val He Arg Arg Leu Asp Glu Thr Val Val 1 5 10 15 Asn Arg He Ala Ala Gly Glu Val He Gin Arg Pro Ala Asn Ala He 20 25 30 Lys Glu Met He Glu Asn Cys Leu Asp Ala Lys Ser Thr Ser He Gin 35 40 45 Val He Val Lys Glu Gly Gly Leu Lys Leu He Gin He Gin Asp Asn 50 55 60 Gly Thr Gly He Arg Lys Glu Asp Leu Asp He Val Cys Glu Arg Phe 65 70 75 80 Thr Thr Ser Lys Leu Gin Ser Phe Glu Asp Leu Ala Ser He Ser Thr 85 90 95 Tyr Gly Phe Arg Gly Glu Ala Leu Ala Ser He Ser His Val Ala His 100 105 110 Val Thr He Thr Thr Lys Thr Ala Asp Gly Lys Cys Ala Tyr Arg Ala 115 120 125 Ser Tyr Ser Asp Gly Lys Leu Lys Ala Pro Pro Lys Pro Cys Ala Gly 130 135 140 Asn Gin Gly Thr Gin He Thr Val Glu Asp Leu Phe Tyr Asn He Ala 145 150 155 160 Thr Arg Arg Lys Ala Leu Lys Asn Pro Ser Glu Glu Tyr Gly Lys He 165 170 175 Leu Glu Val Val Gly Arg Tyr Ser Val His Asn Ala Gly He Ser Phe 180 185 190 Ser Val Lys Lys Gin Gly Glu Thr Val Ala Asp Val Arg Thr Leu Pro 195 200 205 Asn Ala Ser Thr Val Asp Asn He Arg Ser He Phe Gly Asn Ala Val 210 215 220 Ser Arg Glu Leu He Glu He Gly Cys Glu Asp Lys Thr Leu Ala Phe 225 230 235 240 Lys Met Asn Gly Tyr He Ser Asn Ala Asn Tyr Ser Val Lys Lys Cys 245 250 255 He Phe Leu Leu Phe He Asn His Arg Leu Val Glu Ser Thr Ser Leu 260 265 270 Arg Lys Ala He Glu Thr Val Tyr Ala Ala Tyr Leu Pro Lys Asn Thr 275 280 285 His Pro Phe Leu Tyr Leu Ser Leu Glu He Ser Pro Gin Asn Val Asp 290 295 300 Val Asn Val His Pro Thr Lys His Glu Val His Phe Leu His Glu Glu 305 310 315 320 Ser He Leu Glu Arg Val Gin Gin His He Glu Ser Lys Leu Leu Gly 325 330 335 Ser Asn Ser Ser Arg Met Tyr Phe Thr Gin Thr Leu Leu Pro Gly Leu 340 345 350 Ala Gly Pro Ser Gly Glu Met Val Lys Ser Thr Thr Ser Leu Thr Ser 355 360 365 Ser Ser Thr Ser Gly Ser Ser Asp Lys Val Tyr Ala His Gin Met Val 370 375 380 Arg Thr Asp Ser Arg Glu Gin Lys Leu Asp Ala Phe Leu Gin Pro Leu 385 390 395 400 Ser Lys Pro Leu Ser Ser Gin Pro Gin Ala He Val Thr Glu Asp Lys 405 410 415 Thr Asp He Ser Ser Gly Arg Ala Arg Gin Gin Asp Glu Glu Met Leu 420 425 430 Glu Leu Pro Ala Pro Ala Glu Val Ala Ala Lys Asn Gin Ser Leu Glu 435 440 445 Gly Asp Thr Thr Lys Gly Thr Ser Glu Met Ser Glu Lys Arg Gly Pro 450 455 460 Thr Ser Ser Asn Pro Arg Lys Arg His Arg Glu Asp Ser Asp Val Glu 465 470 475 480 Met Val Glu Asp Asp Ser Arg Lys Glu Met Thr Ala Ala Cys Thr Pro 485 490 495 Arg Arg Arg He He Asn Leu Thr Ser Val Leu Ser Leu Gin Glu Glu 500 505 510 He Asn Glu Gin Gly His Glu Val Leu Arg Glu Met Leu His Asn His 515 520 525 Ser Phe Val Gly Cys Val Asn Pro Gin Trp Ala Leu Ala Gin His Gin 530 535 540 Thr Lys Leu Tyr Leu Leu Asn Thr Thr Lys Leu Ser Glu Glu Leu Phe 545 550 555 560 Tyr Gin He Leu He Tyr Asp Phe Ala Asn Phe Gly Val Leu Arg Leu 565 570 575 Ser Glu Pro Ala Pro Leu Phe Asp Leu Ala Met Leu Ala Leu Asp Ser 580 585 590 Pro Glu Ser Gly Trp Thr Glu Glu Asp Gly Pro Lys Glu Gly Leu Ala 595 600 605 Glu Tyr He Val Glu Phe Leu Lys Lys Lys Ala Glu Met Leu Ala Asp 610 615 620 Tyr Phe Ser Leu Glu He Asp Glu Glu Gly Asn Leu He Gly Leu Pro 625 630 635 640 Leu Leu He Asp Asn Tyr Val Pro Pro Leu Glu Gly Leu Pro He Phe 645 650 655 He Leu Arg Leu Ala Thr Glu Val Asn Trp Asp Glu Glu Lys Glu Cys 660 665 670 Phe Glu Ser Leu Ser Lys Glu Cys Ala Met Phe Tyr Ser He Arg Lys 675 680 685 Gin Tyr He Ser Glu Glu Ser Thr Leu Ser Gly Gin Gin Ser Glu Val 690 695 700 Pro Gly Ser Trp Lys Trp Thr Val Glu His He Val Tyr Lys Ala Leu 705 710 715 720 Arg Ser His He Leu Pro Pro Lys His Phe Thr Glu Asp Gly Asn He 725 730 735 Leu Gin Leu Ala Asn Leu Pro Asp Leu Tyr Lys Val Phe Glu Arg Cys 740 745 750

Claims: CLAIMS 1. A method of discriminating proliferating from non-proliferating cells in a tissue, comprising the steps of: contacting a tissue comprising cells with antibodies specifically immunoreactive with a mismatch repair protein to form antibody-antigen complexes; determining the presence of said antibody-antigen complexes in said cells, said presence indicating proliferating cells. 2. The method of claim 1 wherein the step of deteπiiining is by means of immunohistochemistry. 3. The method of claim 1 wherein the step of determining is by means of immunofluorescence. 4. The method of claim 1 wherein the step of determining is by means of fluorescence activated cell sorting. 5. The method of claim 1 wherein the mismatch repair protein is hMSH2. 6. The method of claim 1 wherein the mismatch repair protein is hMLHl . 7. The method of claim 1 wherein the mismatch repair protein is hPMS2. 8. A method of determining a defect in a mismatch repair gene in tumor cells, comprising the steps of: contacting a tissue comprising tumor cells with antibodies specifically immunoreactive with a mismatch repair protein, to form antibody-antigen complexes; determining nuclear localization of said antibody-antigen complexes, absence of nuclear staining indicating a defect in a mismatch repair gene. 9. The method of claim 8 wherein said step of determining is by means of immunohistochemistry. 10. The method of claim 8 wherein said step of determining is by means of immunofluorescence. 11. The method of claim 8 wherein the mismatch repair protein is hMSH2. 12. The method of claim 8 wherein the mismatch repair protein is hMLHl . 13. The method of claim 8 wherein the mismatch repair protein is hPMS2. 14. A method of monitoring the effectiveness of anti-cancer therapy in neoplastic tissue, comprising the steps of: contacting a sample of a neoplastic tissue which has been subjected to an anti-cancer therapy with antibodies specifically immunoreactive with a mismatch repair protein to form antibody-antigen complexes; deteπnining the amount of said antibody-antigen complexes in said sample; comparing the amount of antibody-antigen complexes in said sample with an amount determined at an earlier time, a reduction in the amount of antibody-antigen complexes indicating effective therapy. 15. The method of claim 14 wherein said step of deteraiining is by immunohistochemistry. 16. The method of claim 14 wherein said step of determining is by immunofluorescence. 17. The method of claim 14 wherein said step of determining is by fluorescent activated cell sorting. 18. The method of claim 14 wherein said step of determining is by enzyme linked immunosorbent assay. 19. The method of claim 14 wherein the mismatch repair protein is hMSH2. 20. The method of claim 14 wherein the mismatch repair protein is hMLHl. 21. The method of claim 14 wherein the mismatch repair protein is hPMS2. 22. A method to discriminate proliferating from non-proliferating cells, comprising the steps of: preparing a lysate of cells to be tested; contacting said lysate with antibodies specifically immunoreactive with a mismatch repair protein, to form antibody-antigen complexes; determining the amount of antibody-antigen complexes formed in said lysate, a lysate of test cells which provides more antibody-antigen complexes than control lysates of non-tumor cells indicating that the test cells are proliferating. 23. The method of claim 22 wherein said step of determining is by means of enzyme linked immunosorbent assay. 24. The method of claim 22 wherein the mismatch repair protein is hMSH2. 25. The method of claim 22 wherein the mismatch repair protein is hMLHl. - 29 - 26. The method of claim 22 wherein the mismatch repair protein is hPMS2. 27. A method to discriminate proliferating from non-proliferating cells, comprising the steps of: isolating nuclei of cells to be tested; preparing a lysate of said nuclei of said cells to be tested; contacting said lysate with antibodies specifically immunoreactive with a mismatch repair protein, to form antibody-antigen complexes; determining the amount of antibody-antigen complexes formed in said lysate, a lysate of nuclei which provides more antibody-antigen complexes than control lysates of non-tumor cell nuclei indicating that the test cells are proliferating. 28. The method of claim 27 wherein said step of determining is performed by means of enzyme linked immunosorbent assay. 29. The method of claim 27 wherein the mismatch repair protein is hMSH2. 30. The method of claim 27 wherein the mismatch repair protein is hMLHl. 31. The method of claim 27 wherein the mismatch repair protein is hPMS2. 32. A method of identifying tumor-bearing individuals, comprising the steps of: detecting auto-antibodies to a mismatch repair protein in a human, wherein presence of said auto-antibodies indicates the presence of a tumor in the human. 33. The method of claim 32 wherein the mismatoh repair protein is hMSH2. 34. The method of claim 32 wherein the mismatch repair protein is hMLHl. 35. The method of claim 32 wherein the mismatoh repair protein is hPMS2.

Inventors: BURRELL MARILEE, HILL DAVID E, KINZLER KENNETH W, VOGELSTEIN BERT, BURRELL, MARILEE, HILL, DAVID, E., KINZLER, KENNETH, W., VOGELSTEIN, BERT
Applicants: UNIV JOHNS HOPKINS, THE JOHNS HOPKINS UNIVERSITY
Application year: 1996
Main classification: G01N33
IPC codes: C12Q1, G01N33